Patents by Inventor Alessandra Di Pietro

Alessandra Di Pietro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PD-1 AXIS BINDING ANTAGONIST TO TREAT CANCER WITH GENETIC MUTATIONS IN SPECIFIC GENES
    Publication number: 20220241263
    Abstract: The present disclosure describes combination therapies comprising a PD-1 axis binding antagonist, wherein the cancer has been pre-determined to have one or more genetic mutations in one or more genes, to have certain gene expression profiles, and/or to have other biomarkers.
    Type: Application
    Filed: May 29, 2020
    Publication date: August 4, 2022
    Inventors: Marat Alimzhanov, Keith Anthony Ching, Alessandra Di Pietro, Xinmeng Mu, Paul Brian Robbins
  • PD-L1 ANTAGONIST COMBINATION TREATMENTS
    Publication number: 20210069326
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: November 19, 2020
    Publication date: March 11, 2021
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • PD-L1 antagonist combination treatments
    Patent number: 10869924
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Grant
    Filed: June 15, 2016
    Date of Patent: December 22, 2020
    Assignees: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian Andrews, Shihao Chen, Alessandra Di Pietro, David Fontana, Zelanna Goldberg, Chia-Yang Lin, Hua Long, Marcella Martignoni, Dimitry Serge Antoine Nuyten, Aron David Thall, Adrian Woolfson
  • PD-L1 Antagonist Combination Treatments
    Publication number: 20180169232
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death Ligand 1 receptor (PD-L1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.
    Type: Application
    Filed: June 15, 2016
    Publication date: June 21, 2018
    Applicants: MERCK PATENT GMBH, PFIZER INC.
    Inventors: Glen Ian ANDREWS, Shihao CHEN, Alessandra DI PIETRO, David FONTANA, Zelanna GOLDBERG, Chia-Yang LIN, Hua LONG, Marcella MARTIGNONI, Dimitry Serge Antoine NUYTEN, Aron David THALL, Adrian WOOLFSON
  • COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS
    Publication number: 20160060344
    Abstract: The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor.
    Type: Application
    Filed: August 28, 2015
    Publication date: March 3, 2016
    Inventors: Rajesh Narwal, Marlon C. Rebelatto, Keith Steele, Paul Robbins, Ross Anthony Stewart, John A. Blake-Haskins, Joyson J. Karakunnel, Ramy Ibrahim, Aiman Shalabi, Alessandra Di Pietro, Li Shi, Shengyan Hong, Paul Stockman, Marc Ballas, Mohammed M. Dar